Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells

T. Yokoyama, E. Iwado, Y. Kondo, H. Aoki, Y. Hayashi, M. M. Georgescu, R. Sawaya, K. R. Hess, G. B. Mills, H. Kawamura, Y. Hashimoto, Y. Urata, Toshiyoshi Fujiwara, S. Kondo

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Oncolytic adenoviruses are a promising tool in cancer therapy. In this study, we characterized the role of autophagy in oncolytic adenovirus-induced therapeutic effects. OBP-405, an oncolytic adenovirus regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad, OBP-301) with a tropism modification (RGD) exhibited a strong antitumor effect on glioblastoma cells. When autophagy was inhibited pharmacologically, the cytotoxicity of OBP-405 was attenuated. In addition, autophagy-deficient Atg5-/- mouse embryonic fibroblasts (MEFs) were less sensitive than wild-type MEFs to OBP-405. These findings indicate that OBP-405-induced autophagy is a cell killing effect. Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication. Mice harboring intracranial tumors treated with OBP-405 and temozolomide survived significantly longer than those treated with temozolomide alone, and mice treated with OBP-405 and the rapamycin analog RAD001 survived significantly longer than those treated with RAD001 alone. The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma.

Original languageEnglish
Pages (from-to)1233-1239
Number of pages7
JournalGene Therapy
Volume15
Issue number17
DOIs
Publication statusPublished - 2008

Fingerprint

temozolomide
Autophagy
Glioblastoma
Adenoviridae
Antineoplastic Agents
Sirolimus
Fibroblasts
Neoplasms
Tropism
Therapeutic Uses
Therapeutics

ASJC Scopus subject areas

  • Genetics

Cite this

Yokoyama, T., Iwado, E., Kondo, Y., Aoki, H., Hayashi, Y., Georgescu, M. M., ... Kondo, S. (2008). Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Therapy, 15(17), 1233-1239. https://doi.org/10.1038/gt.2008.98

Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. / Yokoyama, T.; Iwado, E.; Kondo, Y.; Aoki, H.; Hayashi, Y.; Georgescu, M. M.; Sawaya, R.; Hess, K. R.; Mills, G. B.; Kawamura, H.; Hashimoto, Y.; Urata, Y.; Fujiwara, Toshiyoshi; Kondo, S.

In: Gene Therapy, Vol. 15, No. 17, 2008, p. 1233-1239.

Research output: Contribution to journalArticle

Yokoyama, T, Iwado, E, Kondo, Y, Aoki, H, Hayashi, Y, Georgescu, MM, Sawaya, R, Hess, KR, Mills, GB, Kawamura, H, Hashimoto, Y, Urata, Y, Fujiwara, T & Kondo, S 2008, 'Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells', Gene Therapy, vol. 15, no. 17, pp. 1233-1239. https://doi.org/10.1038/gt.2008.98
Yokoyama, T. ; Iwado, E. ; Kondo, Y. ; Aoki, H. ; Hayashi, Y. ; Georgescu, M. M. ; Sawaya, R. ; Hess, K. R. ; Mills, G. B. ; Kawamura, H. ; Hashimoto, Y. ; Urata, Y. ; Fujiwara, Toshiyoshi ; Kondo, S. / Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. In: Gene Therapy. 2008 ; Vol. 15, No. 17. pp. 1233-1239.
@article{dd6c20efa0304fa3b74373231f847917,
title = "Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells",
abstract = "Oncolytic adenoviruses are a promising tool in cancer therapy. In this study, we characterized the role of autophagy in oncolytic adenovirus-induced therapeutic effects. OBP-405, an oncolytic adenovirus regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad, OBP-301) with a tropism modification (RGD) exhibited a strong antitumor effect on glioblastoma cells. When autophagy was inhibited pharmacologically, the cytotoxicity of OBP-405 was attenuated. In addition, autophagy-deficient Atg5-/- mouse embryonic fibroblasts (MEFs) were less sensitive than wild-type MEFs to OBP-405. These findings indicate that OBP-405-induced autophagy is a cell killing effect. Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication. Mice harboring intracranial tumors treated with OBP-405 and temozolomide survived significantly longer than those treated with temozolomide alone, and mice treated with OBP-405 and the rapamycin analog RAD001 survived significantly longer than those treated with RAD001 alone. The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma.",
author = "T. Yokoyama and E. Iwado and Y. Kondo and H. Aoki and Y. Hayashi and Georgescu, {M. M.} and R. Sawaya and Hess, {K. R.} and Mills, {G. B.} and H. Kawamura and Y. Hashimoto and Y. Urata and Toshiyoshi Fujiwara and S. Kondo",
year = "2008",
doi = "10.1038/gt.2008.98",
language = "English",
volume = "15",
pages = "1233--1239",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells

AU - Yokoyama, T.

AU - Iwado, E.

AU - Kondo, Y.

AU - Aoki, H.

AU - Hayashi, Y.

AU - Georgescu, M. M.

AU - Sawaya, R.

AU - Hess, K. R.

AU - Mills, G. B.

AU - Kawamura, H.

AU - Hashimoto, Y.

AU - Urata, Y.

AU - Fujiwara, Toshiyoshi

AU - Kondo, S.

PY - 2008

Y1 - 2008

N2 - Oncolytic adenoviruses are a promising tool in cancer therapy. In this study, we characterized the role of autophagy in oncolytic adenovirus-induced therapeutic effects. OBP-405, an oncolytic adenovirus regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad, OBP-301) with a tropism modification (RGD) exhibited a strong antitumor effect on glioblastoma cells. When autophagy was inhibited pharmacologically, the cytotoxicity of OBP-405 was attenuated. In addition, autophagy-deficient Atg5-/- mouse embryonic fibroblasts (MEFs) were less sensitive than wild-type MEFs to OBP-405. These findings indicate that OBP-405-induced autophagy is a cell killing effect. Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication. Mice harboring intracranial tumors treated with OBP-405 and temozolomide survived significantly longer than those treated with temozolomide alone, and mice treated with OBP-405 and the rapamycin analog RAD001 survived significantly longer than those treated with RAD001 alone. The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma.

AB - Oncolytic adenoviruses are a promising tool in cancer therapy. In this study, we characterized the role of autophagy in oncolytic adenovirus-induced therapeutic effects. OBP-405, an oncolytic adenovirus regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad, OBP-301) with a tropism modification (RGD) exhibited a strong antitumor effect on glioblastoma cells. When autophagy was inhibited pharmacologically, the cytotoxicity of OBP-405 was attenuated. In addition, autophagy-deficient Atg5-/- mouse embryonic fibroblasts (MEFs) were less sensitive than wild-type MEFs to OBP-405. These findings indicate that OBP-405-induced autophagy is a cell killing effect. Moreover, autophagy-inducing therapies (temozolomide and rapamycin) synergistically sensitized tumor cells to OBP-405 by stimulating the autophagic pathway without altering OBP-405 replication. Mice harboring intracranial tumors treated with OBP-405 and temozolomide survived significantly longer than those treated with temozolomide alone, and mice treated with OBP-405 and the rapamycin analog RAD001 survived significantly longer than those treated with RAD001 alone. The observation that autophagy inducers increase OBP-405 antitumor activity suggests a novel strategy for treating patients with glioblastoma.

UR - http://www.scopus.com/inward/record.url?scp=50049112424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049112424&partnerID=8YFLogxK

U2 - 10.1038/gt.2008.98

DO - 10.1038/gt.2008.98

M3 - Article

VL - 15

SP - 1233

EP - 1239

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 17

ER -